Acute postischemic treatment with estrogen receptor-α agonist or estrogen receptor-β agonist improves myocardial recovery

Nicholas D. Vornehm, Meijing Wang, Aaron Abarbanell, Jeremy Herrmann, Brent Weil, Jiangjing Tan, Yue Wang, Megan Kelly, Daniel R. Meldrum

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Background: After ischemia/reperfusion (I/R) injury, female hearts demonstrate improved functional recovery compared with male, which suggests a protective role for estrogen. Acute postischemic treatment with 17-β-estradiol (E2) attenuates myocardial dysfunction. However, it is unknown by which estrogen receptor (ER) E2 mediates this acute cardioprotection during I/R. Therefore, we hypothesize that postischemic infusion of the selective ER-α agonist (4,4',4''-[4-propyl-(1H)-pyrazole-1,3,5-triyl]tris-phenol [PPT]) or the selective ER-β agonist (2,3-bis(4-hydroxyphenyl)-propionitrile [DPN]) will improve myocardial function after I/R injury. Methods: Isolated, perfused hearts (Langendorff) from adult male rats were subjected to 25 minutes of ischemia followed by 40 minutes of reperfusion. Hearts (n = 4-6 per group) were randomly infused with either perfusate, PPT or DPN at 1, 10, or 100 nmol/L throughout reperfusion. After I/R, heart tissue was analyzed for tumor necrosis factor (TNF)-α, interleukin (IL)-1β, vascular endothelial growth factor (VEGF), and lactate dehydrogenase (LDH). Results: Postischemic treatment with 10 nmol/L of PPT significantly improved myocardial function. Additionally, 10 or 100 nmol/L of DPN significantly increased myocardial functional recovery after I/R injury, with maximum benefit at the 10 nmol/L dose. A trend toward lower levels of LDH was noted in DPN- and PPT-treated groups after I/R injury. Neither PPT nor DPN affected myocardial production of TNF-α or IL-1β. However, higher levels of myocardial VEGF were noted in the PPT-treated group compared with controls. Conclusion: Both ER-α and ER-β are involved in mediating E2-induced rapid cardioprotection after I/R injury. Advancing our understanding of both ER subtypes may be useful for the development of novel strategies that may benefit both males and females in response to myocardial ischemia.

Original languageEnglish
Pages (from-to)145-154
Number of pages10
JournalSurgery
Volume146
Issue number2
DOIs
StatePublished - Aug 2009

Fingerprint

Reperfusion Injury
Estrogens
Estrogen Receptors
Reperfusion
Interleukin-1
L-Lactate Dehydrogenase
Vascular Endothelial Growth Factor A
Ischemia
Tumor Necrosis Factor-alpha
Estrogen Receptor beta
Phenol
Myocardial Ischemia
Estradiol
propionitrile

ASJC Scopus subject areas

  • Surgery

Cite this

Acute postischemic treatment with estrogen receptor-α agonist or estrogen receptor-β agonist improves myocardial recovery. / Vornehm, Nicholas D.; Wang, Meijing; Abarbanell, Aaron; Herrmann, Jeremy; Weil, Brent; Tan, Jiangjing; Wang, Yue; Kelly, Megan; Meldrum, Daniel R.

In: Surgery, Vol. 146, No. 2, 08.2009, p. 145-154.

Research output: Contribution to journalArticle

Vornehm, Nicholas D. ; Wang, Meijing ; Abarbanell, Aaron ; Herrmann, Jeremy ; Weil, Brent ; Tan, Jiangjing ; Wang, Yue ; Kelly, Megan ; Meldrum, Daniel R. / Acute postischemic treatment with estrogen receptor-α agonist or estrogen receptor-β agonist improves myocardial recovery. In: Surgery. 2009 ; Vol. 146, No. 2. pp. 145-154.
@article{1b07999463e94b0da1f6bb19bbcf450b,
title = "Acute postischemic treatment with estrogen receptor-α agonist or estrogen receptor-β agonist improves myocardial recovery",
abstract = "Background: After ischemia/reperfusion (I/R) injury, female hearts demonstrate improved functional recovery compared with male, which suggests a protective role for estrogen. Acute postischemic treatment with 17-β-estradiol (E2) attenuates myocardial dysfunction. However, it is unknown by which estrogen receptor (ER) E2 mediates this acute cardioprotection during I/R. Therefore, we hypothesize that postischemic infusion of the selective ER-α agonist (4,4',4''-[4-propyl-(1H)-pyrazole-1,3,5-triyl]tris-phenol [PPT]) or the selective ER-β agonist (2,3-bis(4-hydroxyphenyl)-propionitrile [DPN]) will improve myocardial function after I/R injury. Methods: Isolated, perfused hearts (Langendorff) from adult male rats were subjected to 25 minutes of ischemia followed by 40 minutes of reperfusion. Hearts (n = 4-6 per group) were randomly infused with either perfusate, PPT or DPN at 1, 10, or 100 nmol/L throughout reperfusion. After I/R, heart tissue was analyzed for tumor necrosis factor (TNF)-α, interleukin (IL)-1β, vascular endothelial growth factor (VEGF), and lactate dehydrogenase (LDH). Results: Postischemic treatment with 10 nmol/L of PPT significantly improved myocardial function. Additionally, 10 or 100 nmol/L of DPN significantly increased myocardial functional recovery after I/R injury, with maximum benefit at the 10 nmol/L dose. A trend toward lower levels of LDH was noted in DPN- and PPT-treated groups after I/R injury. Neither PPT nor DPN affected myocardial production of TNF-α or IL-1β. However, higher levels of myocardial VEGF were noted in the PPT-treated group compared with controls. Conclusion: Both ER-α and ER-β are involved in mediating E2-induced rapid cardioprotection after I/R injury. Advancing our understanding of both ER subtypes may be useful for the development of novel strategies that may benefit both males and females in response to myocardial ischemia.",
author = "Vornehm, {Nicholas D.} and Meijing Wang and Aaron Abarbanell and Jeremy Herrmann and Brent Weil and Jiangjing Tan and Yue Wang and Megan Kelly and Meldrum, {Daniel R.}",
year = "2009",
month = "8",
doi = "10.1016/j.surg.2009.04.026",
language = "English",
volume = "146",
pages = "145--154",
journal = "Surgery",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Acute postischemic treatment with estrogen receptor-α agonist or estrogen receptor-β agonist improves myocardial recovery

AU - Vornehm, Nicholas D.

AU - Wang, Meijing

AU - Abarbanell, Aaron

AU - Herrmann, Jeremy

AU - Weil, Brent

AU - Tan, Jiangjing

AU - Wang, Yue

AU - Kelly, Megan

AU - Meldrum, Daniel R.

PY - 2009/8

Y1 - 2009/8

N2 - Background: After ischemia/reperfusion (I/R) injury, female hearts demonstrate improved functional recovery compared with male, which suggests a protective role for estrogen. Acute postischemic treatment with 17-β-estradiol (E2) attenuates myocardial dysfunction. However, it is unknown by which estrogen receptor (ER) E2 mediates this acute cardioprotection during I/R. Therefore, we hypothesize that postischemic infusion of the selective ER-α agonist (4,4',4''-[4-propyl-(1H)-pyrazole-1,3,5-triyl]tris-phenol [PPT]) or the selective ER-β agonist (2,3-bis(4-hydroxyphenyl)-propionitrile [DPN]) will improve myocardial function after I/R injury. Methods: Isolated, perfused hearts (Langendorff) from adult male rats were subjected to 25 minutes of ischemia followed by 40 minutes of reperfusion. Hearts (n = 4-6 per group) were randomly infused with either perfusate, PPT or DPN at 1, 10, or 100 nmol/L throughout reperfusion. After I/R, heart tissue was analyzed for tumor necrosis factor (TNF)-α, interleukin (IL)-1β, vascular endothelial growth factor (VEGF), and lactate dehydrogenase (LDH). Results: Postischemic treatment with 10 nmol/L of PPT significantly improved myocardial function. Additionally, 10 or 100 nmol/L of DPN significantly increased myocardial functional recovery after I/R injury, with maximum benefit at the 10 nmol/L dose. A trend toward lower levels of LDH was noted in DPN- and PPT-treated groups after I/R injury. Neither PPT nor DPN affected myocardial production of TNF-α or IL-1β. However, higher levels of myocardial VEGF were noted in the PPT-treated group compared with controls. Conclusion: Both ER-α and ER-β are involved in mediating E2-induced rapid cardioprotection after I/R injury. Advancing our understanding of both ER subtypes may be useful for the development of novel strategies that may benefit both males and females in response to myocardial ischemia.

AB - Background: After ischemia/reperfusion (I/R) injury, female hearts demonstrate improved functional recovery compared with male, which suggests a protective role for estrogen. Acute postischemic treatment with 17-β-estradiol (E2) attenuates myocardial dysfunction. However, it is unknown by which estrogen receptor (ER) E2 mediates this acute cardioprotection during I/R. Therefore, we hypothesize that postischemic infusion of the selective ER-α agonist (4,4',4''-[4-propyl-(1H)-pyrazole-1,3,5-triyl]tris-phenol [PPT]) or the selective ER-β agonist (2,3-bis(4-hydroxyphenyl)-propionitrile [DPN]) will improve myocardial function after I/R injury. Methods: Isolated, perfused hearts (Langendorff) from adult male rats were subjected to 25 minutes of ischemia followed by 40 minutes of reperfusion. Hearts (n = 4-6 per group) were randomly infused with either perfusate, PPT or DPN at 1, 10, or 100 nmol/L throughout reperfusion. After I/R, heart tissue was analyzed for tumor necrosis factor (TNF)-α, interleukin (IL)-1β, vascular endothelial growth factor (VEGF), and lactate dehydrogenase (LDH). Results: Postischemic treatment with 10 nmol/L of PPT significantly improved myocardial function. Additionally, 10 or 100 nmol/L of DPN significantly increased myocardial functional recovery after I/R injury, with maximum benefit at the 10 nmol/L dose. A trend toward lower levels of LDH was noted in DPN- and PPT-treated groups after I/R injury. Neither PPT nor DPN affected myocardial production of TNF-α or IL-1β. However, higher levels of myocardial VEGF were noted in the PPT-treated group compared with controls. Conclusion: Both ER-α and ER-β are involved in mediating E2-induced rapid cardioprotection after I/R injury. Advancing our understanding of both ER subtypes may be useful for the development of novel strategies that may benefit both males and females in response to myocardial ischemia.

UR - http://www.scopus.com/inward/record.url?scp=67650519417&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650519417&partnerID=8YFLogxK

U2 - 10.1016/j.surg.2009.04.026

DO - 10.1016/j.surg.2009.04.026

M3 - Article

C2 - 19628068

AN - SCOPUS:67650519417

VL - 146

SP - 145

EP - 154

JO - Surgery

JF - Surgery

SN - 0039-6060

IS - 2

ER -